Bibliographic information
GuidelineWHO guidelines for malaria, 3 June 2022.
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Maintained
Originally developed
MDA to reduce transmission of P. falciparum in moderate to high transmission settings: In areas with moderate to high levels of P. falciparum transmission, providing antimalarial medicine through mass drug administration (MDA) to reduce transmission is not recommended.
Recommended in favor
Conditional
Certainty of evidence
Very low
Notes and Remarks
Remarks
- The studies included in the systematic review did not demonstrate evidence that MDA has either a short- or long-term effect on P. falciparum transmission in moderate to high transmission settings.
- Recommendations on MDA to reduce the burden of malaria in moderate to high transmission settings can be found in section 4.2.4.1 MDA for burden reduction. Moderate to high transmission settings are defined as areas with P. falciparum parasite prevalence greater than 10%, or P. falciparum incidence above 250 cases per 1000 population per year [29]. These thresholds should not be regarded as absolutes for determining applicability of MDA.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO guidelines for malaria, 25 November 2022.
Year2022
InstitutionWorld Health Organization
Guideline
WHO guidelines for malaria, 16 October 2023.
Year2023
InstitutionWorld Health Organization
Guideline
WHO Guidelines for malaria, 14 March 2023
Year2023
InstitutionWHO
Guideline
WHO guidelines for malaria, 30 November 2024.
Year2024
InstitutionWHO